BELLUS Health Inc. (TSE:BLU – Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$19.48 and traded as high as C$19.61. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares trading hands.
BELLUS Health Price Performance
The firm has a market capitalization of C$2.47 billion, a P/E ratio of -20.29 and a beta of -0.28. The company has a quick ratio of 16.40, a current ratio of 33.42 and a debt-to-equity ratio of 0.32. The stock’s fifty day moving average is C$19.48.
BELLUS Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Featured Articles
- Five stocks we like better than BELLUS Health
- 3 Best Fintech Stocks for a Portfolio Boost
- United Airlines Soars on Earnings Beat
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- J.B. Hunt Hits the Skids: Lower Prices to Come
- The 3 Best Fintech Stocks to Buy Now
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.